Respiratory drug developer Verona Pharma has named former Galenica CEO David Ebsworth as Non-Executive Chairman of the Board of Directors. Ebsworth succeeds Clive Page, who founded the company in 2006.
The company’s lead product, RPL554, is an inhaled PDE3/PDE4 inhibitor being developed for the treatment of asthma, COPD, and cystic fibrosis. In September 2014, Verona Pharma said that it can fund development of the product up to the start of Phase 2b.
Verona Pharma CEO Jan-Anders Karlsson commented, “As well as being the founder of Verona Pharma, Clive has made an enormous contribution to the company over the years, with his extensive knowledge of respiratory medicines and international reputation in the field. We thank him for all his achievements, as we welcome David to the Board. David’s significant expertise in the pharma industry strongly supports Verona Pharma’s focus on high value commercial opportunities and future growth.”
Read the Verona Pharma press release.
